Supplemental material
Journal of Medical Economics
Volume 27, 2024 - Issue 1
Oncology
Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework
Cillian Copelanda Global Market Access Solutions Sàrl Chardonne, SwitzerlandCorrespondence[email protected]
https://orcid.org/0009-0008-3923-5794
https://orcid.org/0009-0008-3923-5794, Nikos Kotsopoulosa Global Market Access Solutions Sàrl Chardonne, Switzerlandhttps://orcid.org/0000-0002-8248-7697
https://orcid.org/0000-0002-8248-7697, Andrea Favre-Bulleb MSD, Lucerne, Switzerlandhttps://orcid.org/0000-0001-7276-9706
https://orcid.org/0000-0001-7276-9706, Goran Bencinac Value & Implementation Outcomes Research, MSD, Madrid, Spainhttps://orcid.org/0000-0001-6293-8211
https://orcid.org/0000-0001-6293-8211, Demet Sönmezd Value & Implementation Outcomes Research, MSD, Stockholm, Swedenhttps://orcid.org/0009-0007-2914-7531
https://orcid.org/0009-0007-2914-7531 & Stina Salomonssond Value & Implementation Outcomes Research, MSD, Stockholm, Swedenhttps://orcid.org/0000-0002-1556-8075
https://orcid.org/0000-0002-1556-8075